Ralaniten(5-35 μM; 2-3 days) reduces AR-dependent proliferation of LNCaP cells and has no effect on the viability of PC3 human prostate cancer cells that do not express functional AR.[1]
Ralaniten (10-35 μM; 4 hours) inhibits forskolin-induced transactivation of the AR N-terminal domain (NTD) in LNCaP cells.[1]

Ralaniten (100 mg/kg; taken orally twice daily for 28 days; Male NOD-SCID mice bearing subcutaneous tumors were castrated) inhibits VCaP tumor growth in castrated mice.[1]